AstraZeneca gets EC marketing approval for lung cancer drug Tagrisso
AstraZeneca has received full marketing authorisation from the European Commission for Tagrisso for the treatment of adult patients with non-small cell lung cancer.
AstraZeneca
9,990.00p
15:45 15/11/24
FTSE 100
8,060.61
15:45 15/11/24
FTSE 350
4,453.56
15:45 15/11/24
FTSE All-Share
4,411.85
15:45 15/11/24
Pharmaceuticals & Biotechnology
19,259.77
15:45 15/11/24
The full approval is based on the results of the Phase III AURA3 trial, which were presented last year.
The EC has given authorisation for Tagrisso 40mg and 80mg once-daily tablets.
Sean Bohen, executive vice president of Global Medicines Development and chief medical officer at AstraZeneca, said: "The full approval of Tagrisso in the EU is further evidence of our exciting progress in transforming the science of cancer care to deliver life-changing medicines to people most in need.
"Having demonstrated its superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer, Tagrisso has the potential to become the new standard of care for patients with this difficult-to-treat form of lung cancer."
At 1420 BST, the shares were up 0.9% to 4,706p.